Up­dat­ed: Pick­ing up the pieces af­ter lead drug im­plod­ed, Rafael Hold­ings gives up on ear­ly R&D in fa­vor of deals

In the months since Rafael Hold­ings’ lead drug flunked two Phase III tri­als — in metasta­t­ic pan­cre­at­ic can­cer and acute myeloid leukemia — the lit­tle biotech has …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER